CRP apheresis registry for COVID-19

CRP apheresis registry for COVID-19 - CACOV-registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024376

Enrollment

1000

Registered

2021-05-04

Start date

2021-05-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease U09

Interventions

Group 1: CRP apheresis according to the instructions for use of the adsorber PentraSorb CRP in patients with COVID-19

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COVID-19, CRP-apheresis

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
CRP progression	—

Secondary

Measure	Time frame
Length of stay in hospital - Length of stay in the intensive care unit - Days of mandatory ventilation - mortality - Pulmonary tissue damage - Myocardial tissue damage - Inflammation markers - Incidence of adverse effects of CRP apheresis	—

Countries

Germany

Contacts

Public ContactBurghard Thiesen

Pentracor GmbH

thiesen@pentracor.de+49 (0)3302 209449-35

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026